- Home
- EONR vs SNGX Comparison
EONR vs SNGX Comparison
Compare EONR & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EONR
- SNGX
- Stock Information
- Founded
- EONR 2020
- SNGX 1987
- Country
- EONR United States
- SNGX United States
- Employees
- EONR N/A
- SNGX N/A
- Industry
- EONR
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- EONR
- SNGX Health Care
- Exchange
- EONR NYSE
- SNGX Nasdaq
- Market Cap
- EONR 6.0M
- SNGX 6.5M
- IPO Year
- EONR N/A
- SNGX 1987
- Fundamental
- Price
- EONR $0.50
- SNGX $2.16
- Analyst Decision
- EONR Strong Buy
- SNGX
- Analyst Count
- EONR 1
- SNGX 0
- Target Price
- EONR $4.50
- SNGX N/A
- AVG Volume (30 Days)
- EONR 352.0K
- SNGX 199.2K
- Earning Date
- EONR 04-15-2025
- SNGX 05-09-2025
- Dividend Yield
- EONR N/A
- SNGX N/A
- EPS Growth
- EONR N/A
- SNGX N/A
- EPS
- EONR N/A
- SNGX N/A
- Revenue
- EONR $20,269,293.00
- SNGX $119,371.00
- Revenue This Year
- EONR $95.25
- SNGX N/A
- Revenue Next Year
- EONR $68.81
- SNGX N/A
- P/E Ratio
- EONR N/A
- SNGX N/A
- Revenue Growth
- EONR N/A
- SNGX N/A
- 52 Week Low
- EONR $0.35
- SNGX $1.68
- 52 Week High
- EONR $3.15
- SNGX $14.83
- Technical
- Relative Strength Index (RSI)
- EONR N/A
- SNGX 51.88
- Support Level
- EONR N/A
- SNGX $1.97
- Resistance Level
- EONR N/A
- SNGX $2.23
- Average True Range (ATR)
- EONR 0.00
- SNGX 0.17
- MACD
- EONR 0.00
- SNGX 0.02
- Stochastic Oscillator
- EONR 0.00
- SNGX 86.36
About EONR EON RESOURCES INC
EON Resources Inc is an independent upstream energy company focused on maximizing total returns to its shareholders through the development of onshore oil and natural gas properties in the United States. Its current focus is as an upstream energy company producing oil and gas properties in the Permian Basin.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).